• 21
  • 8
  • Favorite

Why Cathie Wood Is Bullish On Iovance Biotherapeutics (IOVA)

Benzinga2021-05-24

Cathie Wood-led Ark Investment Management is betting that despite recent setbacks Iovance Biotherapeutics Inc IOVA 3.73% will benefit from its compelling tumor-infiltrating lymphocyte (TIL) immunotherapy.

What Happened: IOVA shares have declined 32% since Tuesday after the California-based biotech startup delayedits Biologics License Application (BLA) until the first half of 2022 because of FDA feedback on its potency tests.

The delay in the program is attributed to the FDA’s second request for additional data regarding potency assays, which are a series of tests that prove the company can consistently manufacture the product in question.

Soon after, IOVA announced CEO Maria Fardis is leaving the company after five years in the role and that General Counsel Frederick Vogt would be stepping in as interim CEO. Shares fell 39% on Wednesday after the announcement.

The New York-based investment firm started piling up shares in the company last week and holds 18.26 million IOVA shares, worth about $450.64 million, according to Ark’s data as of Friday’s trade.

The Ark Genomic Revolution ETF (BATS:ARKG) and theArk Innovation ETF ARKK 0.75% carry the stake in IOVA.

“We believe that Iovance’s TILs will continue to be the most compelling therapy for solid tumors in the market and that Iovance has the most robust TIL data set,” the Cathie Wood-led firm said in a note to investors.

“Furthermore, in our view, Iovance is trail-blazing the FDA regulatory process and likely will get FDA approval for its TIL therapy to treat melanoma, a very difficult-to-treat disease with high unmet need.”

Price Action: IOVA shares closed 3.73% lower at $18.05 on Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment8

  • YQ17
    ·2021-05-24
    Just follow
    Reply
    Report
  • hww1
    ·2021-05-24
    like + comment thnx!!
    Reply
    Report
    Fold Replies
    • YQ17
      Done
      2021-05-24
      Reply
      Report
  • Zhenghao
    ·2021-05-24
    Good choice!!! Help like and comment thanks
    Reply
    Report
  • ProfitsAll
    ·2021-05-24
    Wow. Let’s see how long it will be in profits 
    Reply
    Report
    Fold Replies
    • Zhenghao
      Nice
      2021-05-24
      Reply
      Report
  • priswong
    ·2021-05-24
    Like
    Reply
    Report
    Fold Replies
  • honglilim
    ·2021-05-24
    Likee
    Reply
    Report
    Fold Replies
    • honglilim
      comment
      2021-05-24
      Reply
      Report
    • priswong
      hello
      2021-05-24
      Reply
      Report
    • boeyms
      ok
      2021-05-24
      Reply
      Report
  • clementboey
    ·2021-05-24
    Comment
    Reply
    Report
    Fold Replies
    • hww1
      ok
      2021-05-24
      Reply
      Report
    • kyawkh
      ok
      2021-05-24
      Reply
      Report
    • boeyms
      done
      2021-05-24
      Reply
      Report
  • boeyms
    ·2021-05-24
    Wow
    Reply
    Report
    Fold Replies
    View more 1 comments
 
 
 
 

Most Discussed

 
 
 
 
 

7x24

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email:uservice@ttm.financial